• References

    Abrams P, Alexopoulou O, Abs R, et al. Optimalization and cost management of lanreotide-Autogel therapy in acromegaly.
    Eur J Endocrinol.

    Acromegaly. EBSCO DynaMed website. Available at: Updated May 9, 2014. Accessed June 4, 2014.

    Acromegaly treatment consensus workshop participants: guidelines for acromegaly management.
    J Clin Endocrinol Metab. 2002; 87:4054-4058.

    Cook DM. AACE Acromegaly Guidelines Taskforce. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly.
    Endoc Pract. 2004;10:213-225.

    Glustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly: a consensus statement.
    J Clin Endocrinol Metab. 2000;85:526-529.

    Katznelson L, Atkinson JL, Cook DM, Ezzat SZ, Hamrahian AH, Miller KK.
    American association of clinical endocrinologists medical guidelines for clinical
    practice for the diagnosis and treatment of acromegaly - 2011 update: executive summary.
    Endocr Pract. 2011;17(4):636-646.

    Melmed S. Medical progress: acromegaly.
    N Engl J Med. 2006;355:2558-2573.

    Paisley AN, Trainer PJ. Medical treatment in acromegaly.
    Curr Opin Pharmacol. 2003;3:672-677.

    Sherlock M, Woods C, Sheppard MC. Medical therapy in acromegaly.
    Nat Rev Endocrinol. 2011;7(5):291-300.

    Trainer PJ, Drake WM, Katzneison L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant.
    N Engl J Med. 2000; 342:1171-1177.

  • Resources

    National Institute of Diabetes & Digestive & Kidney Diseases

    Pituitary Network Association

  • Canadian Resources

    Canadian Society of Endocrinology and Metabolism